[Table_Title] 证券研究报告 23Q4 高基数下短期承压，24 年有望稳健增长 公司研究 [Table_ReportDate] 2024年04月01日 [Table_ReportType] 公司点评报告 [T事ab件le：_ 1S）um同ma仁ry堂]发布2023年年度报告，2023年公司实现营业收入 178.61 [同Ta仁bl堂e_（Sto6c0k0A0n8dR5a）nk] 亿元，同比增长16.19%；实现归母净利润16.69 亿元，同比增长16.92%; 实现扣非归母净利润16.57亿元，同比上升18.32%；经营性现金流量净额 投资评级 增持 18.69 亿元，同比下降39.58%；2023年公司EPS为1.217元/股，同比增 上次评级 增持 无 长16.91%。2）同仁堂公告，公司合计拟派发现金红利6.86亿元，占归母 净利润比例为41.09%。 [唐Ta爱b金le_医Au药th行o业r]首席分析师 执业编号：S1500523080002 点评： 联系电话：19328759065  2023 年净利润增速较快，医药商业收入增速亮眼。据公司公告，2023 邮箱：tangaijin@ci ...

2024 年 04 月 01 日 公司研究 评级：买入 (维持 ) 研究所： [Table_Title] 商业增长亮眼，二线品种放量加速 证券分析师： 周小刚 S0350521090002 zhouxg@ghzq.com.cn ——同仁堂（ ） 年年报点评报告 600085 2023 最近一年走势 事件 : 同仁堂3月28日发布2023年年报：2023年公司实现营业收入178.61 亿元，同比增长16.19%；归母净利润16.69亿元，同比增长16.92%； 扣非归母净利润16.57亿元，同比增长18.32%。 公司2023年Q4单季度实现营收41.4亿元，同比下滑7.44%；归母净 利润2.78亿元，同比下滑34.47%；扣非归母净利润2.79亿元，同比下 滑31.83%。 投资要点 : 相对沪深300表现 2024/03/29 表现 1M 3M 12M 同仁堂 -7.9% -23.7% -23.1%  2023年公司商业部分增长亮眼 分板块来看，2023年公司工业 沪深300 0.6% 3.1% -11.7% 板块营收110.79亿元，同比增长12.6%；商业板块营收102.46亿 元，同比增长20.8 ...

公司报告 | 年报点评报告 同仁堂（600085） 证券研究报告 2024年03月 31日 投资评级 业绩贴近预告上限，工业+商业齐增长 行业 医药生物/中药Ⅱ 6个月评级 买入（维持评级） 当前价格 40.99元 事件： 目标价格 元 2024 年 3 月 29 日，同仁堂披露2023 年年度报告，2023 年公司实现营业 收入178.61亿元，同比+16.19%；实现归母净利润16.69亿元，同比+16.92%； 基本数据 实现扣非归母净利润 16.57 亿元，同比+18.32%。2023Q4 单季度公司实现 A股总股本(百万股) 1,371.47 营业收入41.40亿元，同比-7.44%；归母净利润2.78亿元，同比-34.47%； 流通A股股本(百万股) 1,371.47 扣非归母净利润2.79亿元，同比-31.83%。 A股总市值(百万元) 56,216.57 工业+商业齐增长，前五名系列表现稳健 流通A股市值(百万元) 56,216.57 2023年公司医药工业板块实现收入110.79亿元，同比+12.60%；其中心脑 每股净资产(元) 9.52 血管类产品实现收入43.88亿元，同比+8.02% ...

证券研究报告 公 2024年03月31日 司 报 告 同仁堂(600085) 行 业： 医药生物/中药Ⅱ │ 公 投资评级： 买入（维持） 司 当前价格： 40.99元 业绩稳定增长，费用持续优化 年 目标价格： 55.60元 报 点 事件： 评 基本数据 公司发布2023年年度报告，2023全年实现收入178.61亿元（yoy+16.19%）， 总股本/流通股本(百万股) 1,371.47/1,371.47 归母净利润 16.69 亿元（yoy+16.92%），扣非归母净利润 16.57 亿元 流通A股市值(百万元) 56,216.57 （yoy+18.32%）。单Q4季度公司实现收入 41.40亿元（yoy-7.44%），归母 每股净资产(元) 9.52 净利润2.78亿元（yoy-34.47%），扣非归母净利润2.79亿元（yoy-31.83%）。 资产负债率(%) 32.68 ➢ 主营业务增长良好，四季度短期承压 一年内最高/最低(元) 64.28/39.71 公司医药工业业务实现营收 110.79 亿元（yoy+12.60%），毛利率 46.97% （yoy-1.98pct），其中心脑血管、补益类产 ...

关于北京同仁堂股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所（特殊普通合伙） 目 录 关于北京同仁堂股份有限公司非经营性资金占用及其他关联资金 往来的专项说明 北京同仁堂股份有限公司 2023年度非经营性资金占用及其他关联 资金往来情况汇总表 1 本专项说明仅供同仁堂公司披露年度报告时使用，不得用作任何其他用 途。 致同会计师事务所 （特殊普通合伙） 中国注册会计师 郑建彪 中国注册会计师 何姗姗 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 关于北京同仁堂股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字（2024）第 110A003915 号 北京同仁堂股份有限公司全体股东： 我们接受北京同仁堂股份有限公司（以下简称"同仁堂公司"）委托， 根据中国注册会计师执业准则审计了同仁堂公司 2023 年 12 月 31 日的合并及公 司资产负债表，2023 年度合并及公司利润表、 ...

2024年3月29日 公司研究 Q4 业绩受子公司拖累，提质增效仍是主旋律 ——同仁堂（600085.SH）2023 年年报点评 要点 增持（维持） 当 前价：41.68元 事件：公司发布2023年年报，实现营业收入、归母净利润、扣非归母净利润分 别为178.61/16.69/16.57亿元，同比+16.19%/16.92%/18.32%；经营性净现金 流18.69亿元，同比-39.58%；EPS（基本）1.22元。拟向全体股东每10股派 作者 发现金红利5.0元（含税），股利支付率为41.09%。业绩基本符合预增公告。 分析师：黄素青 点评： 执业证书编号：S0930521080001 021-52523570 Q4业绩受到同仁堂国药拖累，大品种战略持续推进：2023Q4营收、归母净利 huangsuqing@ebscn.com 润、扣非净利润分别为41.40/2.78/2.79亿元，同比-7.44%/-34.47%/-31.83%， 业绩承压与高基数、费用投入加大、同仁堂国药收入下滑有关。分业务看，2023 年医药工业和商业分别实现营收110.79亿元（同比+12.60%）、102.46亿元（同 市场数据 ...

Financial Performance - Net profit attributable to shareholders in 2023 was RMB 1,668,834,509.63[4] - Revenue in 2023 increased by 16.19% year-on-year to 1,786,089.15 million RMB[17] - Net profit attributable to shareholders of the listed company rose by 16.92% to 166,883.45 million RMB in 2023[17] - Operating cash flow decreased by 39.58% to 186,949.19 million RMB in 2023[17] - Total assets grew by 11.22% to 3,008,945.02 million RMB at the end of 2023[17] - Basic earnings per share increased by 16.91% to 1.217 RMB in 2023[18] - Weighted average return on equity (ROE) improved by 0.70 percentage points to 13.42% in 2023[18] - Revenue in Q4 2023 was 413,951.15 million RMB, with net profit attributable to shareholders at 27,814.22 million RMB[20] - The company's total revenue for 2023 reached 10.5 billion yuan, representing a year-on-year growth of 8.5%[108] - Net profit attributable to shareholders increased by 12.3% to 1.2 billion yuan in 2023[108] - The company's gross profit margin improved to 45.6%, up 1.2 percentage points from the previous year[108] - Operating cash flow grew by 15.7% to 2.3 billion yuan in 2023[108] - R&D expenditure increased by 18.9% to 350 million yuan, accounting for 3.3% of total revenue[108] - The company's revenue reached a record high of $96.77 billion in the September quarter, driven by strong iPhone sales in China[110] - The company's net income increased by 15% year-over-year to $23.45 billion[110] - The company's operating cash flow grew by 20% to $34.56 billion[110] - The company's R&D expenditure increased by 25% to $6.78 billion, focusing on new product development and technological innovation[110] - The company's gross margin improved by 2% to 42%, driven by cost optimization and product mix[110] - The company's total assets increased by 10% to $400 billion, reflecting strong financial health[110] - The company's debt-to-equity ratio decreased by 5% to 0.5, indicating improved financial leverage[110] - The company's earnings per share (EPS) increased by 18% to $5.67, reflecting strong profitability[110] Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares[4] - The total distributable profit for 2023 is RMB 8,370,702,732.85[4] - The company distributed a cash dividend of 439 million yuan for the year 2022[29] - The company's cash dividend for 2023 is RMB 438,870,483.84, accounting for 30.78% of the net profit attributable to ordinary shareholders[149] - The net profit attributable to ordinary shareholders in 2023 is RMB 1,425,811,705.31[149] Company Information and Structure - The company's registered address was changed to No. 33, Tiangui Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing[12] - The company's A-share stock is listed on the Shanghai Stock Exchange with the stock code 600085[14] - The company's legal representative is Di Shubing[10] - The company's total share capital is 1,371,470,262 shares[4] - The company's registered capital is RMB 1,371,470,262[4] - The company's website is gf.tongrentang.com[12] - The company's email address is tongrentang@tongrentang.com[12] - The company's board of directors held a total of 7 meetings in 2023, with 3 being in-person and 4 being a combination of in-person and teleconference[133] - The company's independent directors and external supervisors receive an annual allowance of 120,000 RMB (tax included) each, as approved by the 2020 annual shareholders' meeting[128] - The company's chairman, Di Shubing, transferred to Tongrentang Group during the reporting period, and his salary is now paid by Tongrentang Group instead of the company[128] - The company's board of directors has several specialized committees, including the Audit Committee, Nomination Committee, Compensation and Evaluation Committee, Strategy and Investment Committee, and Legal Construction Committee[134] - The company's directors, supervisors, and senior management personnel receive basic salaries according to the company's salary system and performance-based salaries based on the completion of annual economic and technical indicators[127] - The company's independent directors and external supervisors do not receive any other compensation from the company, its controlling shareholders, or other affiliated units besides the annual allowance[128] - The company's board of directors held its 24th meeting on December 29, 2023, and all proposals were approved[131] - The company's directors attended all 7 board meetings in 2023, with some attending in person and others via teleconference[132] - The company's board of directors held its 18th to 23rd meetings in 2023, with all proposals being approved[130] - The company's board of directors has a Compensation and Evaluation Committee consisting of Qiao Yanjiang, Wang Guihua, and Wang Zhao[134] - The company held seven audit committee meetings in 2023, focusing on reviewing the 2022 annual financial report, internal control self-evaluation, and the appointment of auditors[136] - The company's total number of employees is 16,777, with 1,998 in the parent company and 14,779 in major subsidiaries[142] - The company's employee composition includes 2,300 production personnel, 7,477 sales personnel, and 3,720 technical personnel[142] - The company's educational background of employees includes 497 with postgraduate degrees, 4,965 with bachelor's degrees, and 6,615 with associate degrees[142] - The company established Beijing Tongrentang Tongxin Pharmaceutical Co., Ltd. as a wholly-owned subsidiary of Beijing Tongrentang Commercial Investment Group Co., Ltd. in 2023[140] - The company plans to set up a branch in Daxing Exhibition and Sales Center and revised the "Company External Investment Management Measures" in 2023[140] - The company conducted a 2023 annual selection and commendation activity for advanced collectives and individuals to motivate employees and enhance core competitiveness[144] - The company reviewed and approved the 2023 Q1, Q2, and Q3 reports, as well as related party transactions and procurement framework agreements[136][137] - The company revised several internal management systems, including the "External Financial Assistance Management System" and "Related Party Transaction Management System" in 2023[136] - The company emphasized strict compliance with legal and regulatory requirements in its 2023 mid-year and year-end legal compliance work reports[141] - The company's largest shareholder, China Beijing Tongrentang (Group) Co., Ltd., holds 719,308,540 shares, representing 52.45% of the total shares[189] - The second-largest shareholder, China Europe Medical Health Hybrid Securities Investment Fund, holds 54,553,870 shares, representing 3.98% of the total shares[189] - The company's total number of ordinary shareholders at the end of the reporting period was 76,865[188] - The company's subsidiary, Tongrentang Commercial, signed a share transfer agreement with Yiyang Group to transfer shares of Anshan Traditional Chinese Medicine Hospital and Shijiazhuang Traditional Chinese Medicine Hospital, but the transfer process is not yet completed[183] - The company's board of directors approved a proposal for entrusted loans from the controlling shareholder to the company and its subsidiaries, with details disclosed in the 2023-034 announcement[183] - The company's total funds received from related parties amounted to 3,544,332.62 RMB, primarily from advertising fees[182] - The company's total funds provided to related parties at the end of the period were 530,000 RMB, mainly for guarantee deposits[182] - The company's controlling shareholder, Tongrentang Group, reported unaudited consolidated financial revenue of 23.57 billion yuan and a profit of 3.31 billion yuan for 2023[194] - China Construction Bank - E Fund CSI 300 Healthcare ETF increased its shareholding to 10,191,090 shares, representing 0.74% of total shares[191] - E Fund CSI 300 Healthcare ETF added 134,300 shares through securities lending, totaling 10,325,390 shares or 0.75% of total shares[192] - Tongrentang Group directly holds 1.40% of Tongrentang Technology (1666.HK) shares[194] - E Fund - China Life Insurance - Traditional Insurance - E Fund China Life Stock Growth Traditional Disposable Single Asset Management Plan holds 5,940,338 shares, representing 0.43% of total shares[190] - Macao Monetary Authority - Own Funds holds 5,876,582 shares, representing 0.43% of total shares[190] - China Construction Bank - ICBC Credit Suisse Frontier Medical Stock Fund holds 5,768,900 shares, representing 0.43% of total shares[190] - E Fund - China Life Insurance - Dividend Insurance - E Fund China Life Stock Growth Stock Portfolio Single Asset Management Plan (Disposable) holds 6,816,926 shares, representing 0.50% of total shares[193] - ICBC - China Europe Medical Innovation Stock Fund exited with 4,177,113 shares, representing 0.30% of total shares[193] - Bank of China - ICBC Credit Suisse Healthcare Industry Stock Fund exited with 1,458,482 shares, representing 0.11% of total shares[193] Research and Development - R&D expenses grew by 28.68% to RMB 279.82 million, reflecting increased investment in research and development[42] - R&D investment totaled 383,045,446.41 yuan, accounting for 2.14% of total revenue, with a 4.63% increase compared to the previous year[51][53] - The company has 508 R&D personnel, making up 3.03% of the total workforce, with 12 holding PhDs and 85 holding master's degrees[52] - The company's R&D team focused on new product development, variety cultivation, and standard system construction, achieving partial results in areas such as classical formulas and Qingnao Xuanqiao Dripping Pills[72] - Key R&D projects include the secondary development of Tongren Niuhuang Qingxin Pills and exploratory research on potential varieties to enhance their value[72] - The company completed internal standard research for Chuan Niuxi and addressed production quality issues, while also planning ahead for the conservation of endangered medicinal resources[72] - R&D expenditures include direct costs such as employee salaries, R&D expenses, testing fees, material costs, and shared equipment and facility costs allocated based on usage[76] - Development phase expenditures are capitalized if they meet specific criteria, including technical feasibility, intent to complete, market potential, and sufficient resources[76] - Capitalized development expenditures are recorded as development costs on the balance sheet and converted to intangible assets upon project completion[76] - R&D investment in 2023 was 2.14% of operating revenue, higher than the industry average of 1.83%[77] - R&D investment accounted for 1.89% of net assets, ranking in the middle of the industry[77] - Key R&D projects include safety evaluation of Bozi Yangxin Pills (1,446.12万元) and clinical research of Fufang Xiaohuoluo Pills (1,220.03万元)[80] Sales and Marketing - Sales expenses totaled 343,663.20万元, accounting for 19.24% of operating revenue, higher than the industry average of 12.37%[84] - Employee compensation accounted for 48.15% of total sales expenses (165,488.85万元)[82] - Market expansion expenses were 64,366.03万元, representing 18.73% of total sales expenses[82] - The company's e-commerce activities, such as the "618" and "Double 11" promotions, saw Wuzi Yanzong Wan and Suoyang Gujing Wan maintain their top sales positions in the male health category on Tmall for three consecutive years[28] - The company established a product marketing sub-center to effectively utilize visitor traffic to drive product sales[26] - The company's advertising and promotion expenses in the retail sector were 159.8275 million yuan, a year-on-year increase of 1.75%[64] - The gross profit margin of the pharmaceutical retail business was 31.11%, an increase of 0.16 percentage points year-on-year[64] - The company's revenue from cardiovascular and cerebrovascular products was 4.38842 billion yuan, with a gross profit margin of 57.62%[70] - Revenue from tonic products was 1.7298117 billion yuan, with a gross profit margin of 37.39%[70] - Revenue from heat-clearing products was 614.5686 million yuan, with a gross profit margin of 34.97%[70] - The company plans to focus on large-scale aggregation and implement the big product strategy in 2024, aiming to enhance product sales and market penetration[97] - The company will strengthen brand services and optimize after-sales services to meet the growing health needs of the public[97] - The company will continue to innovate in marketing and product development to maintain its competitive edge in the traditional Chinese medicine market[98] - The company plans to integrate online and offline channels to promote its products and services, focusing on retail network expansion and e-commerce development[95] - E-commerce sales grew by 35% year-on-year, contributing 15% to total revenue in 2023[108] - The company launched 12 new products in 2023, which contributed 8% to total sales revenue[108] Production and Operations - The company successfully transferred the drug approval numbers for three products: Angong Niuhuang Wan, Dahuoluo Wan, and Niuhuang Qingxin Wan (Jufang), increasing the reserve of drugs listed in the medical insurance catalog[29] - By the end of the reporting period, Tongrentang Commercial had 1,001 retail stores[29] - The company launched the Yuyao series of products and completed the formulation of cultivation plans for several exclusive products[26] - The company conducted clinical research on several products, including preliminary verification of the efficacy of Angong Niuhuang Wan in treating ischemic stroke[28] - The company completed the phased acceptance of digital production lines in its branches, achieving the extraction and transmission of production process data[32] - The company's "Non-traditional Large Honey Pill Craftsmanship and Intelligent Technology Research" project was recognized as an outstanding project in the National Cultural and Tourism Technology Innovation Engineering[32] - The company's "Key Technology Development and Industrialization Project for Continuous Manufacturing of Traditional Chinese Medicine Extracts and Preparations" was nominated for the 2023 Beijing Science and Technology Award[32] - The company owns over 800 drug specifications, with more than 400 in regular production[79] - The company has multiple medicinal material planting bases to ensure supply of key raw materials[86] - The company plans to expand its retail network by opening 200 new stores in 2024, targeting a 10% increase in market coverage[108] - A new production facility with an investment of 500 million yuan is under construction, expected to be operational by Q3 2024[108] - The company successfully completed the acquisition of a regional pharmaceutical distributor for 280 million yuan, enhancing its distribution network[108] - The company opened a total of 1,001 retail stores by the end of the reporting period, with 59 new stores added in 2023, including 62 newly established stores and 3 closures[61] - Retail revenue from Chinese and Western medicines and herbal pieces accounted for 81.75% of total retail revenue, an increase from 79.12% in 2022[63] - The company's retail pharmacies purchased Chinese and Western medicines and herbal pieces worth approximately 3.975 billion yuan from the top 5 suppliers, a year-on-year increase of 14.46%[63] - 630 retail pharmacies have established traditional Chinese medicine clinics, accounting for 62.94% of the total retail pharmacies[63] - 783 retail pharmacies have obtained the qualification of "medical insurance designated retail pharmacies," accounting for 78.22% of the total retail pharmacies[63] - The company's subsidiary, Tongrentang Commercial, signed a share transfer agreement with Yiyang Group to transfer shares of Anshan Traditional Chinese Medicine Hospital and Shijiazhuang Traditional Chinese Medicine Hospital, but the transfer process is not yet completed[183] - The company's board of directors approved a proposal for entrusted loans from the controlling shareholder to the company and its subsidiaries, with details disclosed in the 2023-034 announcement[183] - The company's total funds received from related parties amounted to 3,544,332.62 RMB, primarily from advertising fees[182] - The company's total funds provided to related parties at the end of the period were 530,000 RMB, mainly for guarantee deposits[182] - The company's controlling shareholder, Tongrentang Group, reported unaudited consolidated financial revenue of 23.57 billion yuan and a profit of 3.31 billion yuan for 2023[194] - China Construction Bank - E Fund CSI 300 Healthcare ETF increased its shareholding to 10,191,090 shares, representing 0.74% of total shares[191] - E Fund CSI 300 Healthcare ETF added 134,300 shares through securities lending, totaling 10,325,390 shares or 0.75% of total shares[192] - Tongrentang Group directly holds 1.40% of Tongrentang Technology (1666.HK) shares[194] - E Fund - China Life Insurance - Traditional Insurance - E Fund China Life Stock Growth Traditional Disposable Single Asset Management Plan holds 5,940,338 shares, representing 0.43% of total shares[190] - Macao Monetary Authority - Own Funds holds 5,876,582 shares, representing 0.43% of total shares[190] - China Construction Bank - ICBC Credit Suisse Frontier Medical Stock Fund holds 5,768,900 shares, representing 0.43% of total shares[190] - E Fund - China Life Insurance - Dividend Insurance - E Fund China Life Stock Growth Stock Portfolio Single Asset Management Plan (Disposable) holds

证券代码：600085 证券简称：同仁堂 公告编号：2024-003 北京同仁堂股份有限公司 第九届董事会第二十五次会议决议公告 表决结果：同意 11 票，反对 0 票，弃权 0 票。 (三) 审议通过了《2023 年度利润分配预案》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 会议召开情况 北京同仁堂股份有限公司（以下简称公司）第九届董事会第二十五次会议于 2024 年 3 月 27 日在公司会议室以现场结合通讯会议方式召开。本次会议通知已 提前送达全体董事，与会各位董事均已知悉与本次会议所议事项的相关必要信息。 本次董事会会议应出席董事 11 人，实际出席 11 人。公司全体监事及部分高级管 理人员列席了本次会议。会议由董事长邸淑兵先生主持，会议的召开和表决程序 符合《中华人民共和国公司法》及《北京同仁堂股份有限公司章程》的有关规定。 二、 会议审议情况 (一) 审议通过了《2023 年度总经理工作报告》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 (二) 审议通过了《2023 年度财务决算报告》 经 ...

北京同仁堂股份有限公司 二〇二三年度 审计报告 致同会计师事务所（特殊普通合伙） 目 录 | 审计报告 | 1-4 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-6 | | 财务报表附注 | 7-127 | 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 审计报告 致同审字（2024）第 110A004883 号 北京同仁堂股份有限公司全体股东： 一、审计意见 我们审计了北京同仁堂股份有限公司（以下简称同仁堂公司）财务报表， 包括 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及公司利润 表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表 附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了同仁堂公司 2023年 1 ...

北京同仁堂股份有限公司 董事会审计委员会对 2023 年度年审会计师事务所 履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》和《北京同仁堂股份有限公司章程》（以 下简称《公司章程》）等规定和要求，北京同仁堂股份有限公司（以下简称公司） 董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计 委员会对会计师事务所 2023 年度履行监督职责的情况汇报如下： 一、 2023 年年审会计师事务所基本情况 (一) 会计师事务所基本情况 会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下简称致同所） 成立日期：1981 年 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO 0014469 公司于 2023 年 3 月 24 日召开第九届董事会第十八次会议，审议通过了《关 于续聘会计师事务所及决定其报酬的预案》，后该议案于2023年6月26日经2022 年年度股东大会审议通 ...